Personalized mRNA Vaccine (mRNA-4157/V940)
Type: vaccine
Status: FDA Breakthrough Designation. Australia Phase 3.
Developer: Moderna/Merck
Breakthrough Summary
No summary available.
Mechanism of Action
Custom mRNA encoding up to 34 patient-specific neoantigens + Keytruda
Year: 2024-2026